Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | MTOR | P42345 | 18/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.60 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.60 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.60 |
| ▸ | LTK | P29376 | 1/20 | 0.60 |
| ▸ | CDK7 | P50613 | 1/20 | 0.60 |
| ▸ | NEK2 | P51955 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.60 |
| ▸ | PRKDC | P78527 | 1/20 | 0.60 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439358 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL2282904 | 0.89 | MTOR (1.00) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL2281969 | 0.89 | MTOR (1.00) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL7922488 | 0.88 | MTOR (0.78) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL2283748 | 0.88 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL15747929 | 0.87 | PIK3CA (0.93) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL2279824 | 0.87 | PIK3CA (0.77) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL2284471 | 0.86 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL15747754 | 0.85 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL20430353 | 0.84 | MTOR (0.73) | PIK3CAMTORPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | claimed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | claimed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | claimed |
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2356120-B1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791131-B2 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | PFIZER INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2356120-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2010038165-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190326-A1 | IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PIK3CA, PIK3CD, PIK3R5 | PIK3CA 1/4885MTOR 4/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.